1. Executive Summary
2. Research Methodology
3. Psoriasis
3.1 Overview
3.1.1 Symptoms
3.1.2 Causes
3.2 Types
3.2.1 Plaque psoriasis
3.2.2 Guttate psoriasis
3.2.3 Pustular psoriasis
3.2.4 Inverse psoriasis
3.2.5 Erythrodermic psoriasis
3.3 Diagnosis & Treatment
3.3.1 Diagnosis
3.3.2 Treatment
4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Products
4.2.2 Market Share by Therapeutic Class
4.2.3 Market Share by Mode of Administration
4.2.4 Market Share by Region
5. Drug Analysis
5.1 Biologics
5.1.1 Tumor necrosis factor-alpha (TNF-alpha) Inhibitors
5.1.1.1 Overview
5.1.1.2 Market Sizing (Actual & Forecasted)
5.1.2 Interleukin (IL) Inhibitors
5.1.2.1 Overview
5.1.2.2 Market Sizing (Actual & Forecasted)
5.1.3 T-cell Inhibitors
5.1.3.1 Overview
5.1.3.2 Market Sizing (Actual & Forecasted)
6. Regional Analysis
6.1 North America
6.1.1 Market Sizing (Actual & Forecasted)
6.1.2 The US
6.1.2.1 Market Sizing (Actual & Forecasted)
6.1.2.2 Market Share by Therapeutic Class
6.2 Europe
6.2.1 Market Sizing (Actual & Forecasted)
6.2.2 The UK
6.2.2.1 Market Sizing (Actual & Forecasted)
6.2.3 Germany
6.2.3.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 Market Sizing (Actual & Forecasted)
6.3.2 Japan
6.3.2.1 Market Sizing (Actual & Forecasted)
7. Market Dynamics
7.1 Industry Trends & Developments
7.1.1 Increasing Adoption of Interleukin (IL) Inhibitors
7.1.2 Uptake of Biosimilars
7.1.3 Patent Expirations
7.1.4 Mergers & Acquisitions
7.2 Growth Drivers
7.2.1 Rising Incidences of Autoimmune Diseases
7.2.2 Changing Lifestyle
7.2.3 Ageing Population
7.2.4 Increasing Availability of Biologics & Biosimilars
7.2.5 Growing Awareness
7.3 Challenges
7.3.1 Stringent Regulations
7.3.2 Side-effects of Oral Drugs
7.3.3 High Cost of Drugs
8. Competitive Landscape
8.1 Financial Analysis
8.2 Market Share Analysis
9. Company Profiles
9.1 AbbVie Inc.
9.2 Amgen Inc.
9.3 Johnson & Johnson
9.4 Novartis AG
9.5 Eli Lilly & Company